Cervical cancer is a diagnosis no woman wants to receive, and navigating the disease can be challenging. A type of cancer ...
The FDA has approved cosibelimab (marketed under the brand name Unloxcyt), a new drug for adults with advanced cutaneous squamous cell carcinoma (CSCC), a type of skin cancer.
The U.S Food and Drug Administration said on Friday it has approved Checkpoint Therapeutics' drug for treatment of a type of ...
Checkpoint Therapeutics' Unloxcyt wins FDA approval for advanced cSCC, marking the company's entry into the U.S. market, valued over $1 billion annually.
The FDA has approved cosibelimab under the brand name Unloxcyt for the treatment of metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC that’s not curable by surgery or ...
Knowledge of the association between human papillomavirus (HPV) and oropharyngeal squamous cell carcinoma (OPSCC) is poor and did not improve from 2018 to 2020, according to a study published online ...
Unloxcyt was approved by the FDA as a new treatment for patients with locally advanced or metastatic cutaneous squamous cell ...
In the expanding oncology market, Exelixis (EXEL) is gaining attention with its strong pipeline and impressive stock ...
In Australia, anyone needing a facial prosthetic, such as a nose or ear, must pay for it themselves. However, those below the ...